AZD0486 is named as a drug or biological intervention in 2 clinical trials in our UK, China and USA trial registers, 1 of which is recruiting. The lead sponsor is AstraZeneca. Registered phases: Phase 3 and Phase 1. Conditions studied include Large B-cell Lymphoma; B-cell Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07215585 | AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (ClinicalTrials.gov ↗) Large B-cell Lymphoma |
Phase 3 | Recruiting |
| NCT04594642 | A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma (ClinicalTrials.gov ↗) B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Large B-cell Lymphoma | 1 |
| B-cell Non Hodgkin Lymphoma | 1 |
| Diffuse Large B Cell Lymphoma | 1 |
| High-grade B-cell Lymphoma | 1 |
| Follicular Lymphoma | 1 |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 2 |
| Register | AZD0486 trials |
|---|---|
| Clinical trials in UK | 1 |
| Clinical trials in China | 1 |
| Clinical trials in USA | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how AZD0486 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists AZD0486 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.